A Look Back at Pirquet & Schick’s Influential Serum Sickness Study

Ruth Jessen Hickman, MD, is a graduate of the Indiana University School of Medicine. She is a freelance medical and science writer living in Bloomington, Ind.

References

1. von Pirquet C, Schick B. Die Serumkrankheit. Leipzig: Franz Deuticke; 1905. English version, translation by Schick B. Serum Sickness. Baltimore: Williams &Wilkins, 1951.
2. Becker EL. Elements of the history of our present concepts of anaphylaxis, hay fever and asthma. Clin Exp Allergy. 1999 Jul;29: 875–895.
3. From DNA to beer: How did they make diphtheria antitoxin? National Institutes of Health. 2019 Aug (updated).
4. Wendt D, Warnere M. Béla Schick and serum sickness. National Institutes of Health. Circulating Now. 2014 Feb 25.
5. Silverstein AM. A History of Immunology. 2nd ed. London, England: Elsevier; 2009.
6. Wolf IJ. Bela Schick. JAMA. 1968 Jan 1;203(1):44.
7. Turk JL. Von Pirquet, allergy, and infectious diseases: A review. J R Soc Med. 1987 Jan;80(1):31–33.
8. Lawley TJ, Bielory L, Gascon P, et al. A study of human serum sickness. J Invest Dermatol. 1985 Jul;85(1 Suppl):129s–132s.
9. Hunt LW. Recent observations in serum sickness. JAMA. 1932 Sep 10;99(11):909–912.
10. Beilory L. Clinical complications of heterologous antisera administration. J Wilderness Med. 1991 May;2(2):127–139.
11. Weigle WO, Dixon FJ. Relationship of circulating antigen-antibody complexes, antigen elimination, and complement fixation in serum sickness. Proc Soc Exp Biol Med. 1958 Oct;99(1):226–231.
12. Germuth FG Jr. A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type. J Exp Med. 1953 Feb 1;97(2):257–282.
13. Guttmann A, Krasnokutsky S, Pillinger MH, Berhanu A. Pegloticase in gout treatment—safety issues, latest evidence and clinical considerations. Ther Adv Drug Saf. 2017 Dec;8(12):379–388.
14. Lipsky PE, Calabrese LH, Kavanaugh A, et al. Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther. 2014 Mar 4;16(2):R60.
15. Gupta S, Lau K, Harding CO, et al. Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials. EBioMedicine. 2018 Nov;37:366–373.